Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Oral peptides represent a convenient, safety-favorable alternative to injectable biologics. Enlicitide decanoate is a macrocyclic peptide first-in-class oral PCSK9 inhibitor that lowers LDL-C, with maximal efficacy achieved when administered on an empty stomach. WHAT QUESTION DID THIS STUDY ADDRESS?
What Is New? The work reported here demonstrates the de novo invention of a novel macrocyclic peptide, MK-0616, capable of achieving the potency and selectivity of an antibody in a form that can be taken orally. This provides validation and guidance for the use of mRNA display technology, a major advancement in the medicinal chemistry underlying drug discovery. What Are the Clinical Implications?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
